We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Acceleron and Celgene Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration
News

Acceleron and Celgene Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration

Acceleron and Celgene Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration
News

Acceleron and Celgene Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Acceleron and Celgene Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Acceleron Pharma, Inc. has announced it has received the upfront payment from Celgene Corporation following clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the collaboration between the two companies previously announced on February 20, 2008.

The collaboration between Acceleron and Celgene is a joint development, joint commercialization agreement on ACE-011, a first-in-class, novel bone-forming compound, and three discovery stage programs for the treatment of cancer and cancer-related bone loss.

Advertisement